Answers are grounded in this paper and cite their sources.
A case report reveals the effects of RAAS blockade on nephrotic syndrome in IgAN and MCD, suggesting a potential treatment overlap.
IgA nephropathy (IgAN) is the most common form of primary glomerular disease in Asia. It usually presents with hematuria, although presentation with nephrotic syndrome is rare. Minimal change disease (MCD), on the other hand, accounts for approximately 10-15% of adult primary nephrotic syndrome. In rare patients with IgAN presenting with nephrotic syndrome, renal biopsy may reveal features of both IgAN and MCD, termed MCD-IgAN. According to current guidelines, the first-line therapy of IgAN is renin–angiotensin–aldosterone system (RAAS) blockade, whereas glucocorticoids are the standard of care for MCD.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: